First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.

Recruiting

Phase 1

Phase 2

CRB-601-01First-in-human Study of CRB-601-01 to Treat Patients with Advanced Solid Tumor.

Sponsor:

Corbus Pharmaceuticals Inc.

Code:

NCT06603844

Conditions

Solid Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

CRB-601 monoclonal antibody

Anti-PD-1 monoclonal antibody

Immune-priming single lesion SBRT

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-09. This information was provided to ClinicalTrials.gov by Corbus Pharmaceuticals Inc. on 2024-12-24.